Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.

Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO, Spinolo JA, Dicke KA, Horwitz LH, Alexanian R.

Bone Marrow Transplant. 1990 Apr;5(4):265-8.

PMID:
1970939
2.
3.
4.
5.

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.

Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.

J BUON. 2007 Jan-Mar;12(1):41-4.

PMID:
17436400
6.

Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.

Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R.

Br J Haematol. 1993 Feb;83(2):240-4.

PMID:
8457473
7.

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.

Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.

Blood. 1990 Nov 1;76(9):1860-6.

8.

Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.

Hurd DD, Haake RJ, Lasky LC, Christiansen NP, McGlave PB, Bostrom B, Levine EG, Weisdorf DJ, Kim TH, Peterson BA, et al.

Med Pediatr Oncol. 1990;18(6):447-53.

PMID:
1978232
9.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951
10.

Chemotherapy for resistant and relapsing multiple myeloma.

Alexanian R, Barlogie B, Ventura G.

Eur J Haematol Suppl. 1989;51:140-4. Review.

PMID:
2576405
11.

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.

Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1995 Jan 15;85(2):588-96. Review.

12.

Intensive sequential therapy for VAD-resistant multiple myeloma.

Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R.

Leuk Lymphoma. 1994 May;13(5-6):479-84.

PMID:
7915163
14.

High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.

Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD.

Blood. 1989 Sep;74(4):1260-5.

15.

Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.

Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al.

Blood. 1993 Oct 15;82(8):2324-8.

16.

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.

Haematologica. 2006 May;91(5):621-7.

17.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Review.

PMID:
12042984
18.

Update on the treatment of multiple myeloma.

Kyle RA.

Oncologist. 2001;6(2):119-24. Review.

19.

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.

Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.

Bone Marrow Transplant. 1999 Feb;23(3):235-41.

Items per page

Supplemental Content

Support Center